Briobacept (BR 3FC) (CAS: 869881-54-9)
Briobacept is a recombinant fusion protein designed to inhibit B-cell activation by targeting B-lymphocyte stimulator (BLyS), also known as BAFF. It consists of two BLyS receptor (BR3) molecules fused to the Fc domain of human IgG1, allowing it to bind BLyS with high affinity and promote B-cell apoptosis.
Key Features:
- Mechanism of Action: Binds to BLyS, preventing B-cell activation and survival, leading to apoptosis.
- Therapeutic Potential: Investigated as a treatment for autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus.
Applications:
- Autoimmune Disease Research: Used to study and modulate B-cell-mediated immune responses.
- Therapeutic Development: Explored as a treatment to reduce harmful B-cell activity in autoimmune conditions.
Handling and Storage:
- Formulation: Typically provided as a lyophilized powder for reconstitution.
- Storage: Store at -20°C in a dry, light-protected environment.
- Handling Precautions: Use personal protective equipment and ensure proper ventilation.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
